Biogen Inc (BIIB) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Over the past 4 years, Biogen Inc has achieved a revenue compound annual growth rate (CAGR) of 0.1%, while earnings have grown at 2.7% CAGR.
Historical revenue and profitability trends for Biogen Inc
The chart above illustrates Biogen Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of Biogen Inc's business.
How efficiently Biogen Inc converts revenue into profit
Profit margins reveal how much of each dollar of revenue Biogen Inc retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project Biogen Inc to continue growing earnings in the coming year. The consensus analyst rating is 3.8108 based on 37 analysts.
Based on our comprehensive analysis, Biogen Inc (BIIB) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of Biogen Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how Biogen Inc stacks up against similar companies
Explore growth analysis for top stocks
Related: BIIB Valuation, BIIB Dividend, BIIB Financial Health
Compare: BIIB vs AAPL, BIIB vs MSFT, BIIB vs GOOGL